Kopran's Q2 financials show decline in profits, 'Sell' call from MarketsMOJO

Kopran, a smallcap pharmaceutical company, recently declared its financial results for the quarter ending September 2024. The company's stock has been given a 'Sell' call by MarketsMOJO.

According to the financials, Kopran has seen a negative performance in the second quarter of the fiscal year 2024-2025, with a score of -8 compared to 15 in the previous quarter. However, there are some positive aspects to the company's financials. The operating cash flow has been consistently growing over the past three years, with the highest amount of Rs 43.26 crore generated annually. This indicates that the company has been able to generate higher revenues from its business operations.

On the other hand, there are some concerning factors in Kopran's financials. The operating profit to interest ratio has been consistently falling over the past five quarters, indicating a deteriorating ability to manage interest payments. The profit before tax (PBT) has also seen a significant decline of -52.32% year on year, and the profit after tax (PAT) has fallen by -46.4% year on year. The company's operating profit and profit margins have also been on a downward trend.

Overall, Kopran's financial performance for the quarter ending September 2024 has been negative, with a 'Sell' call from MarketsMOJO. Investors should carefully consider these factors before making any investment decisions.